Revisiting treatment paradigms in high-risk smoldering multiple myeloma: Out with the old, in with the new?

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2328-2330

  Ghobrial, Irene M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BHQ 880; BIOLOGICAL MARKER; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; IXAZOMIB CITRATE; LENALIDOMIDE; NEUTRALIZING ANTIBODY; RITUXIMAB; SILTUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; COMPRESSION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; LETTER; MAINTENANCE THERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT CARE; PLASMA CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SMOLDERING MULTIPLE MYELOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84884494663     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.788699     Document Type: Letter

References (14)

1. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590.
2. He Y, Wheatley K, Clark O, et al. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003; ( 1): CD004023.
3. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
4. Badros AZ. Lenalidomide in myeloma-a high-maintenance friend. N Engl J Med 2012; 366: 1836-1838.
5. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
6. Harousseau JL, Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): 155-157.
7. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1146-1183.
8. Detweiler-Short K, Hayman S, Gertz MA, et al. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol 2010; 85: 737-740.
9. Mateos M-V, López-Corral L, Hern ández M, et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: A phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs no treatment. Blood 2011; 118(Suppl. 1): Abstract 991.
10. Lowry L, Ardeshna KM. Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma? Cancer J 2012; 18: 390-395.
11. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785-789.
12. Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013; 27: 680-685.
13. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter fl ow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
14. Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: Results from a prospective clinical study. Leuk Lymphoma 2013 Jan 1. [Epub ahead of print]